Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients


Amylin and calcitonin gene related peptide (CGRP) are related to the same peptide family. Both share 16 out of 37 amino acids and can activate each others receptor. CGRP is implicated in migraine pathophysiology but the role of Amylin and its receptor in migraine is not fully clarified.

Full Title of Study: “Amylin and CGRP Migraine Provocation in Migraine Without Aura Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Other
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: September 30, 2019

Detailed Description

Amylin is a peptide hormone that binds to a G-protein coupled receptor (GPCR). amylin was originally found in the pancreas (Beta Cell of Islets of Langerhans) but also shown to be present in the trigeminal ganglion, hind horn ganglia and perivascular nerve fibers.

Amylin has many similarities with CGRP. Amylin and CGRP share 16 out 37 amino acids. Both peptides can activate the amylin 1 subtype (AMY1)receptor with high affinity and reported to have more similar physiological and pharmacological effects.

In addition, both peptides increase the intracellular concentration of cyclic AMP (cAMP) which has a central role in migraine pathophysiology.

The aim of the study is pin point the role of amylin and amylin receptor compare to CGRP in migraine pathophysiology.


  • Other: Amylin (Pramlintide)
    • Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
  • Other: CGRP
    • CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.

Arms, Groups and Cohorts

  • Other: Amylin (Pramlintide)
    • Pramlintide intravenous infusion 120 micrograms over 20 minutes
  • Other: CGRP
    • CGRP intravenous infusion 30 micrograms over 20 minutes

Clinical Trial Outcome Measures

Primary Measures

  • Migraine incidence
    • Time Frame: 12 hours
    • Before (-10 min) and after infusion (+12 hours) of amlyin compared with before and after infusion of CGRP based on questionnaire reported headache and associated symptoms

Secondary Measures

  • Dilatation of Arteria radialis and arteria temporalis superficialis
    • Time Frame: 2 hours
    • Dermascan will be used to measure the above mentioned Radial and temporal arteries diameter.
  • Facial flushing
    • Time Frame: 2 hours
    • Flushing will measured by laser contrast imaging
  • Plasma blood samples
    • Time Frame: 2 hours
    • Measumrent of amylin and CGRP peptides in the plasma in picomol/L
  • Headache intensity
    • Time Frame: 12 hours
    • Measured by visual analog score (VAS) ( 0 to 10). Change in area under curve (AUC)

Participating in This Clinical Trial

Inclusion Criteria

  • Migraine patients meeting International Headache Society (IHS) criteria for migraine without aura of both sexes, 18-60 year, 50-100 kg.
  • Fertile women should use safe contraception. Fertile women do not include hysterectomized women or women who are postmenopausal for at least 2 years. Safe contraception includes either Intra Uterine Device (IUD), birth control pills, surgical sterilization of the woman or depot progestogen.

Exclusion Criteria

  • Tension Type headache for more than 5 days the month on average in the last year.
  • All other primary headaches .
  • Headache later than 48 hours before trial start.
  • Daily intake of any medicine other than oral contraception.
  • Ingestion of any form of medicinal product later than 4 times the plasma half-life substance (on trial day), except for oral contraception.
  • Pregnant or breastfeeding women.
  • Headache on the test day or later than 48 hours prior to administration of trial medicine / placebo
  • Migraine within 5 days before the trial date.
  • Ancestral information or clinical signs of (on the day of inclusion):
  • Hypertension (systolic blood pressure> 150 mmHg and / or diastolic blood pressure> 100 mmHg)
  • Hypotension (systolic blood pressure <90 mm Hg and / or diastolic blood pressure <50 mmHg)
  • Cardiovascular disease of all kinds, including cerebrovascular disease.
  • Anamnestic or clinical signs of mental illness or abuse.
  • Patients with glaucoma or prostatic hyperplasia
  • Anamnestic or clinical signs of diseases of any kind such as the investigating physician is considered relevant for participation in the trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Danish Headache Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hashmat Ghanizada, MD, Principal investigator – Danish Headache Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.